The Zhitong Finance App learned that Giants Biotech (02367) fell more than 4% in early trading, with an intraday low of HK$21.08, close to the historical low of HK$20.485. As of press release, it decreased by 4.12% to HK$21.42, with a turnover of HK$15.581,700.
According to a research report released by Citigroup, the growth in online sales of cosmetics in China slowed in the third quarter of 2026 compared to the first half of the year, mainly dragged down by international brands. It entered a low season after the 618 promotion, which is in line with the retail data trend of the National Bureau of Statistics. Within the scope of the bank, the Giants Biotech brand's online GMV is recovering from a low base, but the third season is not encouraging enough.
The Zhitong Finance App said, “Can “Double Eleven” start a stock price turnaround war for Giants Biotech (02367) after three months of returning all previous gains? China pointed out that among the highlights of the “Double Eleven” campaign, in addition to observing the campaign sales report data, investors also need to pay attention to Juzi Biotech's new S+ grade ultra-transparent stick in the Kefumei Focus series launched in April this year. This “Double Eleven” sales performance may verify to some extent whether it can be used as a “strategic relay single product” after Giant Biotech's single collagen stick, and then directly determine whether the market believes that the company can switch from “relying on a single explosive product” to a “product matrix-driven” logic.